Research
Hormonal
NSAID use in T2DM patients significantly increases the risk of Acute Kidney Injury (AKI) and cardiovascular events, particularly when combined with antihypertensives or SGLT2 inhibitors.
Avoid oral NSAIDs (like ibuprofen or diclofenac) if you have diabetes, especially if you take blood pressure meds or SGLT2 inhibitors. They significantly raise your risk of kidney injury and heart issues. Use topical NSAIDs or acetaminophen (with liver caution) instead.
GoodSupportsHIGH confidence
NSAID use is associated with an increased risk of hospitalization in high-risk populations... for every 10,000 people treated for 30 days with NSAIDs, there were 20 extra hospitalizations in the diabetes population... The event rate of major adverse cardiovascular events within 30 days of initiation among diclofenac users increased by 50% compared with non-initiators.
Why this rating
Supported by population-based registries and cohort studies with specific hazard ratios.
Source
Type 2 diabetes mellitus and osteoarthritis
Nicola Veronese et al. · Seminars in Arthritis and Rheumatism · 2019
DOI 10.1016/j.semarthrit.2019.01.005
narrative_reviewCited 246×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Type 2 diabetes mellitus (T2DM) acts as an independent pathogenic factor for osteoarthritis (OA) progression and arthroplasty complications through mechanisms of oxidative stress, advanced glycation end-products (AGEs), and insulin resistance, separate from mechanical load.Good
- Paracetamol use in patients with T2DM and Non-Alcoholic Fatty Liver Disease (NAFLD) carries a heightened risk of hepatotoxicity due to shared metabolic pathways and reduced clearance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →